AstraZeneca (AZN) Competitors

$76.90
-0.14 (-0.18%)
(As of 05/17/2024 ET)

AZN vs. NVS, ABBV, ABT, PFE, MRK, SNY, JNJ, VRTX, REGN, and GSK

Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Merck & Co., Inc. (MRK), Sanofi (SNY), Johnson & Johnson (JNJ), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and GSK (GSK). These companies are all part of the "pharmaceutical preparations" industry.

AstraZeneca vs.

Novartis (NYSE:NVS) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations.

13.1% of Novartis shares are held by institutional investors. Comparatively, 20.4% of AstraZeneca shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Novartis has higher revenue and earnings than AstraZeneca. Novartis is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$47.73B4.39$14.85B$7.4113.84
AstraZeneca$45.81B5.20$5.96B$2.0437.70

Novartis currently has a consensus target price of $115.00, indicating a potential upside of 12.12%. AstraZeneca has a consensus target price of $81.00, indicating a potential upside of 5.33%. Given AstraZeneca's higher probable upside, analysts clearly believe Novartis is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
AstraZeneca
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Novartis has a net margin of 31.33% compared to Novartis' net margin of 13.30%. AstraZeneca's return on equity of 32.15% beat Novartis' return on equity.

Company Net Margins Return on Equity Return on Assets
Novartis31.33% 32.15% 13.59%
AstraZeneca 13.30%30.42%11.62%

In the previous week, AstraZeneca had 14 more articles in the media than Novartis. MarketBeat recorded 21 mentions for AstraZeneca and 7 mentions for Novartis. Novartis' average media sentiment score of 0.58 beat AstraZeneca's score of 0.39 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novartis
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AstraZeneca
10 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Novartis received 473 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.42% of users gave Novartis an outperform vote while only 58.06% of users gave AstraZeneca an outperform vote.

CompanyUnderperformOutperform
NovartisOutperform Votes
527
61.42%
Underperform Votes
331
38.58%
AstraZenecaOutperform Votes
54
58.06%
Underperform Votes
39
41.94%

Novartis pays an annual dividend of $2.43 per share and has a dividend yield of 2.4%. AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 2.5%. Novartis pays out 32.8% of its earnings in the form of a dividend. AstraZeneca pays out 94.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis has raised its dividend for 4 consecutive years and AstraZeneca has raised its dividend for 1 consecutive years.

Novartis has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Summary

Novartis beats AstraZeneca on 13 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$238.42B$6.80B$5.23B$7.98B
Dividend Yield2.51%2.72%44.24%3.91%
P/E Ratio37.7012.06113.5115.90
Price / Sales5.20314.362,373.4184.97
Price / Cash14.2534.4236.7931.98
Price / Book6.365.795.504.64
Net Income$5.96B$138.82M$105.95M$217.28M
7 Day Performance-0.36%1.45%1.42%2.90%
1 Month Performance12.18%4.81%4.96%6.66%
1 Year Performance2.82%-3.83%7.89%9.89%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVS
Novartis
2.0413 of 5 stars
$103.31
+1.0%
$115.00
+11.3%
+2.2%$211.17B$47.73B13.9476,057
ABBV
AbbVie
4.5639 of 5 stars
$161.55
+0.2%
$174.31
+7.9%
+16.0%$285.28B$54.32B47.9450,000Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
ABT
Abbott Laboratories
4.9713 of 5 stars
$104.00
-0.7%
$121.50
+16.8%
-4.0%$180.92B$40.11B32.40114,000Insider Selling
Short Interest ↑
Positive News
PFE
Pfizer
4.9959 of 5 stars
$28.35
-0.3%
$35.86
+26.5%
-21.5%$160.65B$58.50B-472.4288,000
MRK
Merck & Co., Inc.
4.6229 of 5 stars
$128.66
-0.5%
$131.33
+2.1%
+15.1%$325.87B$61.40B142.9672,000Analyst Revision
News Coverage
SNY
Sanofi
2.8951 of 5 stars
$49.50
-1.4%
$55.00
+11.1%
-9.6%$125.22B$46.61B24.8786,088Analyst Revision
JNJ
Johnson & Johnson
4.8623 of 5 stars
$151.36
+0.1%
$175.86
+16.2%
-2.4%$364.28B$85.16B9.44131,900Analyst Forecast
Short Interest ↑
VRTX
Vertex Pharmaceuticals
4.1598 of 5 stars
$428.59
-0.3%
$432.18
+0.8%
+31.2%$110.60B$9.87B27.815,400Analyst Upgrade
REGN
Regeneron Pharmaceuticals
4.0624 of 5 stars
$984.64
+0.8%
$981.71
-0.3%
+31.4%$108.50B$13.12B29.0913,450Analyst Forecast
Insider Selling
News Coverage
GSK
GSK
2.2681 of 5 stars
$45.66
+1.1%
N/A+27.7%$94.63B$30.74B16.5470,200News Coverage

Related Companies and Tools

This page (NASDAQ:AZN) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners